Endometriosis After Menopause

Endometriosis beyond menopause: persistence, pathophysiology, and malignant potential

Key Points

Highlights:

• Endometriosis persists and may arise de novo in peri- and post-menopausal women.
• Disease activity extends beyond estrogen dependence, involving immune, epigenetic, and local hormonal mechanisms.

Importance:

• This information challenges the traditional view of endometriosis as a disease confined to reproductive age.
• Also highlights a clinically underrecognized population with distinct diagnostic and oncologic implications.

What's Done Here?

• This paper is a narrative review of peri- and post-menopausal endometriosis.
• It integrates epidemiology, pathophysiology, clinical presentation, imaging, biomarkers, and management strategies.
• Also focuses on HRT-related disease modulation and risk of malignant transformation.

Key Findings:

• Endometriosis identified in ~2–5% of post-menopausal women undergoing surgery; true prevalence is likely underestimated.
• Persistent disease driven by progesterone resistance, immune dysregulation, and epigenetic reprogramming, independent of systemic estrogen.
• Local estrogen production (aromatase activity) and exogenous exposure (HRT, tamoxifen) sustain lesion activity.
• Clinical presentation shifts to non-cyclical pelvic pain, bowel/bladder symptoms, or pelvic masses, often mimicking malignancy.
• Imaging (TVUS, MRI) is essential but not definitive; laparoscopy remains the diagnostic gold standard. 
• Malignant transformation occurs in ~0.3–1.6%, predominantly clear cell and endometrioid carcinoma.
• Biomarkers (CA-125, HE4) have limited diagnostic accuracy; emerging tools remain investigational.
• Surgical management remains primary; HRT requires individualized risk–benefit assessment.

 Strength and Limitations:

• Strengths are: comprehensive synthesis across clinical, biological, and oncologic domains; integrates pathophysiological mechanisms with real-world diagnostic and management challenges.
• Limitations are: narrative-(non-systematic) design; limited high-quality data in post-menopausal populations; reliance on retrospective and observational evidence; lack of standardized diagnostic and surveillance strategies.

From the Editor-in-Chief – EndoNews

"This review addresses a persistent misconception in gynecology—that endometriosis is confined to the reproductive years and resolves with menopause. The evidence synthesized here supports a more nuanced view: endometriosis can persist, and in some cases emerge de novo, in peri- and post-menopausal women, with distinct clinical and biological characteristics.

By integrating epidemiological data, clinical observations, and mechanistic insights, the authors place endometriosis within a broader pathophysiological framework that extends beyond systemic estrogen dependence. Local estrogen production, progesterone resistance, immune dysregulation, and epigenetic reprogramming collectively provide plausible explanations for sustained lesion activity in a hypoestrogenic environment. This perspective reinforces the concept that endometriosis is not solely a hormonally driven condition, but a chronic, multifactorial disease process.

Clinically, the shift from cyclical to non-specific symptomatology complicates recognition. Presentations such as non-cyclical pelvic pain, gastrointestinal or urinary symptoms, and pelvic masses frequently overlap with more common age-related conditions, contributing to diagnostic delay. In this context, maintaining clinical suspicion is essential, particularly when evaluating atypical or unexplained findings in peri- and post-menopausal patients.

The potential for malignant transformation, although limited in absolute terms, introduces an additional layer of complexity. The association with endometrioid and clear cell ovarian carcinoma underscores the importance of careful evaluation and appropriate risk stratification, especially in the presence of long-standing disease or suspicious imaging features.

Importantly, management in this population cannot follow a uniform approach. Decisions regarding surgery, surveillance, and hormone replacement therapy must be individualized, balancing symptom control, comorbidities, and long-term risks. The absence of dedicated, high-quality evidence in this age group highlights a critical gap in current guidelines.

This review reinforces a key principle: endometriosis should be understood as a disease that extends beyond reproductive chronology, requiring a pathophysiology-driven, lifespan-oriented approach to diagnosis and management."

Lay Summary

Endometriosis, traditionally considered a disease of reproductive-age women, expected to regress after menopause.

However, a growing body of evidence challenges this assumption, showing that the disease can persist—or even arise de novo—in peri-menopausal and post-menopausal women.

In a narrative review published in the Journal of Clinical Medicine, the team lead by Dr.Espada Vaquero from Nepean Hospital, Australia, examined the clinical, biological, and management aspects of endometriosis in this underrecognized population.

The authors highlight that persistent disease is not solely dependent on systemic estrogen, but may be sustained by local estrogen production, progesterone resistance, immune dysregulation, and epigenetic changes.

Clinically, presentation often differs from younger patients. Symptoms tend to be non-cyclical and may include chronic pelvic pain, bowel or bladder dysfunction, or pelvic masses—frequently mimicking malignancy and contributing to diagnostic delay.

Importantly, although rare, malignant transformation of endometriosis—particularly into endometrioid and clear cell ovarian carcinoma—remains a key concern in this age group.

Imaging plays a central role in evaluation, but definitive diagnosis may still require surgical and histopathological confirmation.

The authors emphasize that management must be individualized, particularly in the context of hormone replacement therapy, where benefits must be carefully balanced against the potential for disease reactivation.

This review underscores that endometriosis should not be viewed as a condition confined to reproductive years, but as a disease with ongoing clinical and pathophysiological relevance across the lifespan.

Research Source: https://pubmed.ncbi.nlm.nih.gov/41303102/